Centers for Disease Control and Prevention, 25279 [2013-10064]
Download as PDF
<![CDATA[
25279
Federal Register / Vol. 78, No. 83 / Tuesday, April 30, 2013 / Notices
Number of
responses per
respondent
Number of
respondents
Avgerage
burden per
response
(in hrs)
Total burden
(in hrs)
Type of respondents
Form name
School food service personnel ...............................................
SFSNS ........
738
1
15/60
185
Total ................................................................................
.....................
........................
........................
........................
560
Ron A. Otten,
Director, Office of Scientific Integrity, Office
of the Associate Director for Science, Office
of the Director, Centers for Disease Control
and Prevention.
Prevention and the Agency for Toxic
Substances and Disease Registry.
[FR Doc. 2013–10130 Filed 4–29–13; 8:45 am]
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
BILLING CODE 4163–18–P
[FR Doc. 2013–10064 Filed 4–29–13; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
pmangrum on DSK3VPTVN1PROD with NOTICES
The meeting announced below
concerns Evaluation of Treatments and
Services Provided to People with
Duchenne Muscular Dystrophy (DMD),
FOA DD13–002, initial review.
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
Time and Date: 12:00 p.m.–2:00 p.m., May
30, 2013 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters To Be Discussed: The meeting will
include the initial review, discussion, and
evaluation of applications received in
response to ‘‘Evaluation of Treatments and
Services Provided to People with Duchenne
Muscular Dystrophy (DMD), FOA DD13–002,
initial review.’’
Contact Person for More Information: M.
Chris Langub, Ph.D., Scientific Review
Officer, CDC, 4770 Buford Highway NE.,
Mailstop F–46, Atlanta, Georgia 30341,
Telephone: (770) 488–3585, EEO6@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
VerDate Mar<15>2010
13:22 Apr 29, 2013
Jkt 229001
[Docket No. FDA–2013–N–0450]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Abbreviated New
Animal Drug Applications
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
the paperwork associated with
abbreviated new animal drug
applications submitted to the Center for
Veterinary Medicine, FDA.
DATES: Submit either electronic or
written comments on the collection of
information by July 1, 2013.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
PO 00000
Frm 00028
Fmt 4703
Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
SUPPLEMENTARY INFORMATION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
FOR FURTHER INFORMATION CONTACT:
JonnaLynn Capezzuto, Office of
Information Management, Food and
Drug Administration, 1350 Piccard
Drive, PI50–400B, Rockville, MD 20850,
301–796–3794, Jonnalynn.capezzuto@
fda.hhs.gov.
Sfmt 4703
E:\FR\FM\30APN1.SGM
30APN1
]]>Agencies
[Federal Register Volume 78, Number 83 (Tuesday, April 30, 2013)]
[Notices]
[Page 25279]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-10064]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below concerns Evaluation of Treatments and
Services Provided to People with Duchenne Muscular Dystrophy (DMD), FOA
DD13-002, initial review.
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the aforementioned meeting:
Time and Date: 12:00 p.m.-2:00 p.m., May 30, 2013 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the public in accordance
with provisions set forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director, Management Analysis
and Services Office, CDC, pursuant to Public Law 92-463.
Matters To Be Discussed: The meeting will include the initial
review, discussion, and evaluation of applications received in
response to ``Evaluation of Treatments and Services Provided to
People with Duchenne Muscular Dystrophy (DMD), FOA DD13-002, initial
review.''
Contact Person for More Information: M. Chris Langub, Ph.D.,
Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop F-
46, Atlanta, Georgia 30341, Telephone: (770) 488-3585, EEO6@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention
and the Agency for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2013-10064 Filed 4-29-13; 8:45 am]
BILLING CODE 4163-18-P
